Immunovant Inc
NASDAQ:IMVT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Immunovant Inc
NASDAQ:IMVT
|
US |
|
B
|
BAWAG Group AG
XETRA:0B2
|
AT |
|
Towa Corp
TSE:6315
|
JP |
|
Aquafil SpA
MIL:ECNL
|
IT |
|
B
|
Brighthouse Financial Inc
LSE:0HPH
|
US |
|
A
|
Agricultural Bank of China Ltd
XHAN:EK7
|
CN |
|
Tidewater Inc
NYSE:TDW
|
US |
|
J
|
Jack in the Box Inc
XBER:JBX
|
US |
|
Sutro Biopharma Inc
F:S090
|
US |
|
Abacus Storage King
ASX:SKG
|
AU |
Immunovant Inc
Immunovant is a biotechnology company that develops medicines for autoimmune diseases, which are conditions where the immune system attacks the body’s own tissues. Its main work is on antibody drugs that block the FcRn pathway, a mechanism that helps certain harmful antibodies stay in the bloodstream. By lowering those antibodies, the company aims to treat diseases such as myasthenia gravis, thyroid eye disease, and other immune-driven disorders. The company does not sell a broad portfolio of commercial drugs. Instead, it earns money mainly by funding and advancing its drug candidates through research, clinical trials, and regulatory work, often with support from partners and investors rather than product sales. If its programs succeed, it would likely make money later by licensing the drugs, partnering with larger drugmakers, or eventually selling approved treatments into specialty physician markets. Immunovant’s business is different from a traditional drug company because it is focused on a small number of highly targeted therapies rather than many products. That makes the company’s value tied closely to whether its lead programs work in clinical testing and whether doctors and regulators see enough benefit for patients with serious autoimmune disease.
Immunovant is a biotechnology company that develops medicines for autoimmune diseases, which are conditions where the immune system attacks the body’s own tissues. Its main work is on antibody drugs that block the FcRn pathway, a mechanism that helps certain harmful antibodies stay in the bloodstream. By lowering those antibodies, the company aims to treat diseases such as myasthenia gravis, thyroid eye disease, and other immune-driven disorders.
The company does not sell a broad portfolio of commercial drugs. Instead, it earns money mainly by funding and advancing its drug candidates through research, clinical trials, and regulatory work, often with support from partners and investors rather than product sales. If its programs succeed, it would likely make money later by licensing the drugs, partnering with larger drugmakers, or eventually selling approved treatments into specialty physician markets.
Immunovant’s business is different from a traditional drug company because it is focused on a small number of highly targeted therapies rather than many products. That makes the company’s value tied closely to whether its lead programs work in clinical testing and whether doctors and regulators see enough benefit for patients with serious autoimmune disease.
Phase II Win: Roivant reported highly positive Phase II results for brepocitinib in cutaneous sarcoidosis, with all patients on high-dose showing strong clinical improvements and a favorable safety profile.
First-in-Class Potential: There are currently no approved therapies for sarcoidosis; brepocitinib could become the first approved treatment if Phase III is successful.
Busy Pipeline: Multiple registrational studies are fully enrolled or underway, including for brepocitinib in dermatomyositis, NIU, and other indications, with key data readouts expected in the second half of 2026.
Financial Strength: Roivant ended the quarter with $4.5 billion in cash, providing ample runway for planned launches and additional R&D.
Strategic Flexibility: Management highlighted a broad and expanding set of opportunities for brepocitinib and other assets, with capital allocation driven by best opportunities, both internal and external.
